Jan de Swart1, Ho Sze Chan2, Marlies C Goorden3, Alfred Morgenstern4, Frank Bruchertseifer4, Freek J Beekman5, Marion de Jong6, Mark W Konijnenberg2. 1. Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands j.deswart@erasmusmc.nl. 2. Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. 3. Section Radiation, Detection and Medical Imaging, Delft University of Technology, Delft, The Netherlands. 4. European Commission, Joint Research Centre, Institute for Transuranium Elements (ITU), Karlsruhe, Germany. 5. Section Radiation, Detection and Medical Imaging, Delft University of Technology, Delft, The Netherlands MIlabs B.V., Utrecht, The Netherlands Department of Translational Neuroscience, Brain Center Rudolf Magnus, The Netherlands; and. 6. Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands Department of Radiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Abstract
UNLABELLED: The combined α-, γ-, and x-ray emitter (213)Bi (half-life, 46 min) is promising for radionuclide therapy. SPECT imaging of (213)Bi is challenging, because most emitted photons have a much higher energy (440 keV) than common in SPECT. We assessed (213)Bi imaging capabilities of the Versatile Emission Computed Tomograph (VECTor) dedicated to (simultaneous) preclinical imaging of both SPECT and PET isotopes over a wide photon energy range of 25-600 keV. METHODS: VECTor was equipped with a dedicated clustered pinhole collimator. Both the 79 keV x-rays and the 440 keV γ-rays emitted by (213)Bi could be imaged. Phantom experiments were performed to determine the maximum resolution, contrast-to-noise ratio, and activity recovery coefficient for different energy window settings. Additionally, imaging of [(213)Bi-DOTA,Tyr(3)]octreotate and (213)Bi-diethylene triamine pentaacetic acid (DTPA) in mouse models was performed. RESULTS: Using 440 keV γ-rays instead of 79 keV x-rays in image reconstruction strongly improved the resolution (0.75 mm) and contrast-to-noise characteristics. Results obtained with a single 440 keV energy window setting were close to those with a combined 79 keV/440 keV window. We found a reliable activity recovery coefficient down to 0.240 MBq/mL with 30-min imaging time. In a tumor-bearing mouse injected with 3 MBq of [(213)Bi-DOTA,Tyr(3)]octreotate, tumor uptake could be visualized with a 1-h postmortem scan. Imaging a nontumor mouse at 5-min frames after injection of 7.4 MBq of (213)Bi-DTPA showed renal uptake and urinary clearance, visualizing the renal excretion pathway from cortex to ureter. Quantification of the uptake data allowed kinetic modeling and estimation of the absorbed dose to the kidneys. CONCLUSION: It is feasible to image (213)Bi down to a 0.75-mm resolution using a SPECT system equipped with a dedicated collimator.
UNLABELLED: The combined α-, γ-, and x-ray emitter (213)Bi (half-life, 46 min) is promising for radionuclide therapy. SPECT imaging of (213)Bi is challenging, because most emitted photons have a much higher energy (440 keV) than common in SPECT. We assessed (213)Bi imaging capabilities of the Versatile Emission Computed Tomograph (VECTor) dedicated to (simultaneous) preclinical imaging of both SPECT and PET isotopes over a wide photon energy range of 25-600 keV. METHODS: VECTor was equipped with a dedicated clustered pinhole collimator. Both the 79 keV x-rays and the 440 keV γ-rays emitted by (213)Bi could be imaged. Phantom experiments were performed to determine the maximum resolution, contrast-to-noise ratio, and activity recovery coefficient for different energy window settings. Additionally, imaging of [(213)Bi-DOTA,Tyr(3)]octreotate and (213)Bi-diethylene triamine pentaacetic acid (DTPA) in mouse models was performed. RESULTS: Using 440 keV γ-rays instead of 79 keV x-rays in image reconstruction strongly improved the resolution (0.75 mm) and contrast-to-noise characteristics. Results obtained with a single 440 keV energy window setting were close to those with a combined 79 keV/440 keV window. We found a reliable activity recovery coefficient down to 0.240 MBq/mL with 30-min imaging time. In a tumor-bearing mouse injected with 3 MBq of [(213)Bi-DOTA,Tyr(3)]octreotate, tumor uptake could be visualized with a 1-h postmortem scan. Imaging a nontumor mouse at 5-min frames after injection of 7.4 MBq of (213)Bi-DTPA showed renal uptake and urinary clearance, visualizing the renal excretion pathway from cortex to ureter. Quantification of the uptake data allowed kinetic modeling and estimation of the absorbed dose to the kidneys. CONCLUSION: It is feasible to image (213)Bi down to a 0.75-mm resolution using a SPECT system equipped with a dedicated collimator.
Authors: Diane S Abou; Andrew Rittenbach; Ryan E Tomlinson; Paige A Finley; Benjamin Tsui; Brian W Simons; Abhinav K Jha; David Ulmert; Ryan C Riddle; Daniel L J Thorek Journal: Cancer Biother Radiopharm Date: 2020-03-17 Impact factor: 3.099
Authors: Ho Sze Chan; Mark W Konijnenberg; Tamara Daniels; Monique Nysus; Mehran Makvandi; Erik de Blois; Wouter A Breeman; Robert W Atcher; Marion de Jong; Jeffrey P Norenberg Journal: EJNMMI Res Date: 2016-11-21 Impact factor: 3.138